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Objective.T oa n a l y z et h ee ﬀect of total parenteral nutrition (TPN) and enteral nutrition (EN) in patients with acute pancreatitis.
Methods. Randomized controlled trials of TPN and EN in patients with acute pancreatitis were searched in NCBI and CBM
databases and The Cochrane Controlled Trials Register. Six studies were enrolled into the analysis, and the details about the
trial designs, characters of the subjects, results of the studies were reviewed by two independent authors and analyzed by STATA
11.0 software. Results. Compared with TPN, EN was associated with a signiﬁcantly lower incidence of pancreatic infection
complications (RR = 0.556, 95% CI 0.436∼0.709, P = .000), MOF (RR = 0.395, 95% CI 0.272∼0.573, P = .003), surgical
interventions (RR = 0.556, 95% CI 0.436∼0.709, P = .000), and mortality (RR = 0.426, 95% CI 0.238∼0.764, P = .167). There
was no statistic signiﬁcance in non-pancreatitis-related complications (RR = 0.853, 95% CI 0.490∼1.483, P = .017). However,
EN had a signiﬁcantly higher incidence of non-infection-related complications (RR = 2.697, 95% CI 1.947∼3.735, P = .994).
Conclusion. EN could be the preferred nutrition feeding method in patients with acute pancreatitis.
1.Introduction
Acute pancreatitis is an inﬂammatory process that presents
diﬀerent severity degrees, ranging from a mild self-limited
disease, with interstitial edema in the pancreas, to a severe
disease with extensive necrosis [1]. Severe AP with its related
systemic inﬂammatory response (SIR) causes increased
metabolic demands and may progress to multiorgan disease
(MOD). Cigarette smoking is an independent risk factor
for AP (95% conﬁdence interval 1.48 to 3.09) and total
exposure correlates with overall risk [2]. Recurrent attacks
of alcoholic AP, however, were not associated with cigarette
smoking [3] but occurred less frequently in those who
had repeated 6-month counselling sessions (to encourage
sobriety) compared with a single session (8% versus 21%,
P = .042) [4]. These data reinforce the common sense
approach of encouraging drinking cessation.
The clinical course of an attack of AP varies from a short
period of hospitalization with supportive care to prolonged
hospitalization and admittance to an intensive care unit
(ICU) because of the developmentof systemic inﬂammatory
response syndrome (SIRS), multiorgan failure (MOF), and
septic complications. Overall, in about 15% to 20% of
patients, AP progresses to a severe illness with a prolonged
disease course. These severely ill patients may develop
organ failure and/or local complications such as pancreatic
necrosis. Approximately 75% of the patients have mild
disease with mortality below 1% [5]. Mortality increases up
to 20% if the disease progresses to its severe necrotizing form
[6–11],andinthemost severecasesmortalitycanrangefrom
30 to 40% [12, 13]. In severe necrotising pancreatitis, 80%
of all patients are catabolic, with high energy expenditure
and enhanced protein catabolism. The negative nitrogen
balancecanbeasmuchas40g/dayandcanhaveadeleterious
eﬀecton bothnutritional statusanddisease progression [14–
16]. The traditional treatment strategy is total parenteral
nutrition (TPN) giving the inﬂamed pancreas a rest. Thus,
nutritional supply is easily controlled, and adynamic ileus
andpancreaticstimulationareavoided.However,inaddition
to cost and the risk of catheter-related sepsis, TPN may
worsen the inﬂammatory process, lead to metabolic and
electrolyte disturbances, alter gut barrier due to increased
intestinal permeability, and develop sepsis and multiple
organ failure [17].2 Gastroenterology Research and Practice
Many high-quality studies have demonstrated that EN
results in clinically relevant and statistically signiﬁcant risk
reduction of infectious complications, pancreatic infections,
and mortality in patients with predicted severe acute pan-
creatitis. EN has also been shown to be beneﬁcial as an
adjunct to the management of severe acute pancreatitis by
obviating the systemic inﬂammatory response syndrome
and in modifying the course of the disease. On the other
hand, TPN has a deleterious eﬀect on the intestinal barrier
function. Studies performed on animals and human beings
show that TPN may worsen intestinal atrophy and intestinal
and systemic immunity, and thereby it may also contribute
to impair the intestinal mucosa permeability and facilitate
bacterial translocation [1]. The protective role of EN,
compared with parenteral nutritional (PN), in maintaining
the integrity of the gut barrier has been demonstrated in a
rat model of acute pancreatitis. The EN group was found
to have signiﬁcantly less bacterial translocation and a lower
blood endotoxin level than the PN group.
Data of randomized controlled trials have compared the
eﬀect of TEN and TPN. But the results are always not the
same and the eﬀect of therapeutics is still not identiﬁed
because of the small sample sizes. Here, we conducted meta-
analysis comparing enteral nutrition with parenteral nutri-
tion to determine the incidence of complications associated
with these diﬀerent routes of nutritional support [18].
2.Methodsand Materials
2.1.Inclusion Criteria. Allclinicalrandomizedcontrolledtri-
als are performed on adults with predicted severe acute pan-
creatitis and reported in English. In each case, the deﬁnition
of the complication was taken as that given in the primary
trial. The safety outcome included at least one of the fol-
lowing:pancreatitis-related complications,non-pancreatitis-
related complications, non-infection-related complications,
multiple-organfailure (MOF),surgery intervention,hospital
stay, and mortality.
2.2. Exclusion Criteria. The comparison not between TPN
and EN, such as the comparison in TPN, EN and other
traditional trials. The outcome included none of the above.
2.3. Material Collection. We collected all the studies of
randomized controlled trials that compared the eﬀect of
TEN and TPN. Data from full-text articles were retrieved
and checked for consistency by two of us (Heming Quan
and Chuanyong Guo) independently. The NCBI (1966–
2010) and CBM (2005–2010) databases and The Cochrane
Controlled Trials Register [19] were cross-searched for
articles. A bibliographic search in the databases was made
using the following predeﬁned terms: (acute [All Fields]
AND severe [All Fields] AND (“pancreatitis” [MeSH Terms]
OR “pancreatitis” [All Fields]) AND (“enteral nutrition”
[MeSH Terms] OR (“enteral” [All Fields] AND “nutrition”
[All Fields]) OR “enteral nutrition” [All Fields])) OR
((“jejunum” [MeSH Terms] OR “jejunum” [All Fields] OR
“jejunum” [All Fields]) AND (“enteral nutrition” [MeSH
Terms] OR (“enteral” [All Fields] AND “nutrition” [All
Fields]) OR “enteral nutrition” [All Fields] OR (“tube” [All
Fields] AND “feeding” [All Fields]) OR “tube feeding”[All
Fields])) OR (nasogastric [All Fields] AND (“enteral nutri-
tion” [MeSH Terms] OR (“enteral” [All Fields] AND “nutri-
tion” [All Fields]) OR “enteral nutrition” [All Fields] OR
(“tube” [All Fields] AND “feeding” [All Fields]) OR “tube
feeding” [AllFields]))AND(“humans”[MeSHTerms] AND
Clinical Trial [ptyp] AND English [lang] AND “2000/01/1”
[PDat]:“2010/12/31” [PDat]). Six randomized controlled
trials from six countries were included in our study.
2.4. Quality Evaluation. The methodologic quality of the
studies was assessed using a previously published scoring
system, with a quality scale range of 0 to 5 points according
to Jadad score system[16,20].Thisqualityscaleincorporates
method of randomization, masking, and dropouts and
w i t h d r a w a l s .As c o r eo f2o rl e s sr e p r e s e n t sal o w - q u a l i t y
study, whereas a score of at least 3 represents a high-quality
study. The results of Jadad score are presented in Table 2.
2.5. Data Collection. The following parameters were
extracted: design of trials, population, incidence of
pancreatitis, way of nutrition support, and the outcome of
these criteria. We calculated the incidence of pancreatitis
according to APACHE II score, the level of CRP, and the
incidence of CT. The population statistics results included in
the study are presented in Tables 1(a) and 1(b). The eﬀective
endpoints of every trial are presented in Table 3.
2.6. Data Analysis. We analyzed pancreatitis-related
complications, non-pancreatitis-related complications,
non-infection-related complications, surgery intervention,
multiple-organ failure (MOF), and mortality between TEN
and TPN. The data analysis and graphs were performed
using the M-H model with STATA 11.0 (Stata Corp.,
College Station, Tex, USA). We tested heterogeneity between
trials with χ2 tests, with P ≤ .01 indicating signiﬁcant
heterogeneity. The relative risk (RR)was presented with 95%
conﬁdence interval (CI) for dichotomous data using M-H
model. Besides, hospital stay was analyzed as a continuous
variable.
3.Results
Of 138 articles screened, 9 RCTs comparing EN and TPN
were identiﬁed. Only 6 RCTs [20, 22–26] fulﬁlled the criteria
in the meta-analysis. 6 RCTs were included because: (1) an
Acute Physiology and Chronic Health Evaluation (APACHE
II) score ≥ 8; (2) trial group received TEN and control
group received TPN; (3) eﬀective ends include one of
pancreatitis-related complications, non-pancreatitis-related
complications, non-infection-related complications, surgery
intervention, multiple-organ failure (MOF), and mortality.
Five of the six studies are high-quality studies [21]. Random
generation: two studies were opaque envelopes, one study
was odd/even numbers, and two studies were computerizedGastroenterology Research and Practice 3
Table 1
(a) Study characteristicsof the included trials
Authors Years Country No. Patients (EN/PN) APACHE II score (EN/PN) Age (EN/PN) Gender (EN/PN)
Male Female
Louie [23] 2005 UK 10/18 11.8/12.7 65.3/59.0 6/9 4/9
Petrov [25] 2006 Russia 35/34 12/12.5 51/52 27/24 8/10
Gunilla [24] 2006 Sweden 24/26 10/9 71/68 10/14 14/12
Casas [26] 2007 Spain 11/11 >8 61.2/55.6 8/8 3/3
Doley [20] 2009 India 25/25 >8 38.4/41.1 — —
Wu [22] 2010 China 53/54 14/16 52/54 32/21 30/24
(b) Study characteristicsof the included trials
Authors Years Biliary etiology (EN/PN) Ways of nutritional support
Cholelithiasis Alcohol Others
Louie 2005 5/7 2/4 3/7 Nasojejunalfeeding tube, endoscopy
Petrov 2006 11/13 16/15 8/6 Nasojejunal feeding tube, X-ray
Gunilla 2006 14/17 3/4 7/5 Nasogastric feeding tube
Casas 2007 4/7 1/4 6/0 Nasojejunalfeeding tube, endoscopy
Doley 2009 10/13 11/8 4/4 Nasojejunal feeding tube, endoscopy
Wu 2010 — — — Nasojejunalfeeding tube, endoscopy
Table 2: Jadad score.
Authors Years Randomized method Blind Exit/lost to followup Jadad scores
Louie 2005 3-center, computer-generated assignmentplaced in sealed, opaque
envelopes
No Yes 3
Petrov 2006 Computerized random number generation No Yes 3
Gunilla 2006 Single-center, sealed, numbered envelopes No Yes 3
Casas 2007 Computerized random number generation No Yes 3
Doley 2009 Odd/even numbers No Yes 3
Wu 2010 Not mentioned No Yes 2
Table 3: Eﬀective endpoint of every trial.
(a)
Authors Years No. Patients
(EN/PN)
Pancreatitis-related
complications
(EN/PN)
Non-pancreatitis-
related complications
(EN/PN)
Non-infection-related
complications
(EN/PN)
Louie 2005 10/18 3/9 0/3 6/4
Petrov 2006 35/34 14/32 4/11 15/6
Gunilla 2006 24/26 9/4 12/7 17/7
Casas 2007 11/11 1/5 — —
Doley 2009 25/25 16/15 — —
Wu 2010 53/54 12/39 — 41/15
(b)
Authors Years MOF (EN/PN) Mortality (EN/PN) Hospital stay
(EN/PN)
Surgery intervention
(EN/PN)
Louie 2005 7/13 0/3 — —
Petrov 2006 7/17 — — —
Gunilla 2006 1/1 1/0 — —
Casas 2007 0/2 0/2 30.2/30.7 0/3
Doley 2009 — 5/4 42/36 21/21
Wu 2010 8/35 6/23 27/16 12/434 Gastroenterology Research and Practice
Potentially relevant trials identiﬁed and
screened for retrieval (n = 138)
Trials retrieved for more
detailed evaluation (n = 18)
Not randomized
controlled trials (n = 102)
Potentially appropriate trials to be
included in meta-analysis (n = 9)
Trials included in
meta-analysis (n = 6)
Excluded (n = 3)
endpoints of interest
not studied/reported
Excluded (n = 9)
Figure 1: Process of study selection of RCTs.
random number generation. Blind: all patients were ran-
domized to receive either enteral or parenteral feeding, so
none of the studies was blind. Baseline characteristics: all
of the six studies reported the baseline characteristics of
the two groups, four of which performed statistics analysis.
The results indicated that the baseline demographic and
clinical characteristics of the two groups were similar. No
signiﬁcant diﬀerences were found between the two groups
of patients. Loss of followup: all patients in the six studies
were hospitalized and followed up during the study. No
patients were failed to be followed up. Intention-to-treat
analysis and compliance analysis are almost coincident.
These characteristics are presented in Figure 1.
3.1. Pancreatitis-Related Complications. All studies reported
pancreatitis-related complications, including pancreatic
infection, pancreatic abscess, and pancreatic necrosis, not
including infections out of pancreas. By M-H analysis, there
was a signiﬁcantly lower risk of infection in patients who
received enteral nutrition compared to those who received
parenteral nutrition (relative risk of 0.556, 95% conﬁdence
interval 0.436 to 0.709, P = .000, Figure 2). The test result
for heterogeneity between the studies was not signiﬁcant
(P = .13006252).
3.2. Non-Pancreatitis-Related Complications. All studies
reported non-pancreatitis-related complications, including
pneumonia, urinary system infection, and central venous
catheter infection. By M-H analysis, there was no statistic
signiﬁcance in non-pancreatitis-related complications in
patients who received enteral nutrition compared to those
who received parenteral nutrition (relative risk of 0.853,
95% conﬁdence interval 0.490 to 1.483, P = .017, Figure 3).
The test result for heterogeneity between the studies was not
signiﬁcant (P = .826279278).
Gunilla E 2006
Study
Casas 2007
ID
Xing-Mao Wu 2010
Louie 2005
Doley 2009
Petrov 2006
0.56(0.44, 0.71) 100
2.54(0.9, 7.16) 3.71
0.2(0.03, 1.45) 4.94
RR(95% CI)
0.31(0.19, 0.53) 38.15
0.6(0.21, 1.72) 6.35
1.07(0.69, 1.65) 14.81
0.43(0.28, 0.64) 32.05
%
Weight
11 0
Overall (I-squared
= 79.3%,
0.1
P = 0) . 00
Figure 2
3.3. Non-Infection-Related Complications. Except for Casas
and Doley, four of the six studies intimately reported non-
infection-related complications, including adult respiratory
distress syndrome, pancreatic cyst and ﬁstula, diarrhea,
abdominal bloating, and remove of nasal jejunal tube, not
including MOF By M-H analysis, there was a signiﬁcantly
higher risk in patients who received enteral nutrition com-
pared to those who received parenteral nutrition (relative
risk of 2.697, 95% conﬁdence interval 1.947 to 3.735, P =
.994, Figure 4). The test result for heterogeneity between the
studies was signiﬁcant (P = .008212507).
3.4. MOF. Except for Doley, ﬁve of the six studies intimately
reported MOF, By M-H analysis, there was a signiﬁcantly
lowerriskofmortalityinpatientswho receivedenteralnutri-
tion compared to those who received parenteral nutrition
(relativeriskof0.395,95%conﬁdenceinterval0.272to0.573,Gastroenterology Research and Practice 5
Study
ID RR (95% CI)
%
Weight
11 0
Petrov 2006
Gunilla E 2006
Louie 2005
0.35 (0.12, 1) 54.98
1.94 (0.92, 4.08) 32.38
0.25 (0.01, 4.35) 12.65
0.85 (0.49, 1.48) 100
0.1
Overall (I-squared =
75.4%, P = .017)
Figure 3
Study
ID RR (95% CI)
%
Weight
11 0
Xing-Mao Wu 2010
Petrov 2006
Gunilla E 2006
Louie 2005
2.7 (1.95, 3.74) 100
2.78 (1.77, 4.39) 48.92
2.43 (1.07, 5.52) 20.04
2.75 (1.39, 5.41) 21.63
2.7 (0.99, 7.35) 9.41
0.1
Overall (I-squared =
0%, P = .994)
Figure 4
P = .003,Figure 5). The test result for heterogeneity between
the studies was not signiﬁcant (P = .307088503).
3.5. Surgical Interventions. Except for Casas, Doley, and
Wu, three of the six studies intimately reported surgical
interventions. By M-H analysis, there was a signiﬁcantly
lower risk of surgical interventions in patients who received
enteral nutrition compared to those who received parenteral
nutrition (relative risk of 0.501, 95% conﬁdence interval
0.378 to 0.663, P = .000, Figure 6). The test result for
heterogeneity between the studies was not signiﬁcant (P =
.440677966).
3.6. Mortality. Except for Petrov, ﬁve of the six studies
intimately reported mortality. By M-H analysis, there was a
signiﬁcantly lower risk of mortality in patients who received
enteral nutrition compared to those who received parenteral
nutrition (relative risk of 0.426, 95% conﬁdence interval
0.238 to 0.764, P = .167, Figure 7). The test result for
heterogeneity between the studies was not signiﬁcant (P =
.190278767).
3.7. Hospital Stay. Three of the six studies intimately
reported hospital stay. This index is continuous variable.
The two groups could not be compared because most of
the studies did not provide intimate standard deviation.
Petrov 2006
Xing-Mao Wu 2010
Casas 2007
Gunilla E 2006
Louie 2005
0.4(0.19, 0.84) 26.68
0.23(0.12, 0.45) 53.64
0.2(0.01, 3.74) 3.87
1.13(0.07, 17.07) 1.45
0.97(0.59, 1.59) 14.36
0.4(0.27, 0.57) 100
Study
ID RR(95% CI)
%
Weight
11 0 0.1
Overall (I-squared =
74.6%, P = .003)
Figure 5
Xing-Mao Wu 2010
Casas 2007
Doley 2009
0.5 (0.38, 0.66) 100
0.28 (0.17, 0.48) 63.49
0.14 (0.01, 2.48) 5.22
1 (0.79, 1.27) 31.3
Study
ID RR (95% CI)
%
Weight
1 10 0.1
Overall (I-squared
94.6%, P = 0) . 00
Figure 6
But according to the average hospital stay, there was no
signiﬁcant diﬀerenceinhospitalstaybetweenthetwogroups.
This result was also found in other studies [27, 28].
3.8. EN Regimen and Time. Except for Doley and Casas, the
otherpapersallusedsemielementalnutritionasENregimen.
Most of them infused the nutrition at 25mL/h and increased
by 10mL/h every 6 hours. Three of them initiate EN within
24 hours. EN was given for more than seven days in all the
six papers (Table 4).
4.Discussion
This meta-analysis shows that EN, compared with PN, has
important beneﬁcial eﬀects in patients with predicted severe
acute pancreatitis, notably, clinically relevant, and statisti-
cally signiﬁcant risk reduction in pancreatitis-related com-
plications, non-pancreatitis-related complications, multiple-
organ failure (MOF), surgery intervention, and mortality.
But PN is superior to EN in non-infection-related complica-
tions. There is no diﬀerence between EN and PN in hospital
stay. The literatures included in this meta-analysis, except
for Wu, are all high-quality randomized controlled trials
with Jadad score more than three and summarizing the best
available evidence-based data. The statistic characterizations
of the population and the inclusion/exclusion criteria of6 Gastroenterology Research and Practice
Table 4: EN regimen and time.
Author Year EN regimen Initial time Lasting time
Louie 2005 A semielemental product with low fat content was infused at 25mL/h and
increased by 10mL/h every 6 hours, until the target rate was achieved Within 24h 10 days
Petrov 2006 Semielemental nutrition was commenced at a rate of 25mL/h and increased
by 10mL/h every 6h, until the desired caloric intake was reached Within 48h More than 7
days
Gunilla 2006
Semielemental nutrition rate was 25mL/hr and gradually increased daily up
to 100mL/hr if tolerated and needed. The aim was to reach full nutrition
within 72 hours
Within 24h 10 days
Casas 2007 Polymeric diet infusion rate was 25mL/h with increases of 25mL/4h until
requirements were reached Within 72h More than 10
days
Doley 2009 Not mentioned Within 72h More than 14
days
Wu 2010 Semielemental nutrition was given at 20mL/h for 20 hours Within 24h 16 days
Louie 2005
Xing-Mao Wu 2010
Doley 2009
Casas 2007
Gunilla E 2006
0.43(0.24, 0.76) 100
0.25(0.01, 4.35) 7.94
0.27(0.12, 0.6) 70.49
1.25(0.38, 4.12) 12.38
0.2 (0.01, 3.74) 7.73
3.38(0.14, 79) 1.46
Study
ID RR(95% CI)
%
Weight
11 0 0.1
Overall (I-squared =
38.2%, P = .167)
Figure 7
severe acute pancreatitis patients are also the same: (1)
abdominal pain, (2) pancreatic enzymes three times higher
than normal, and (3) APACHE II score ≥ 8. Patients in
the two groups have no diﬀerence in age and gender. Their
diseases are mostly caused by cholelithiasis and alcohol
pancreatitis. This meta-analysis contains seven outcomes of
eﬀectiveness.
4.1. Pancreatitis-Related Complications and Non-Pancreatitis-
Related Complications. To date, there is a substantial sci-
entiﬁc evidence that enteral feeding is superior to total
parenteral nutrition (TPN) [29, 30]. The beneﬁcial eﬀects
of enteral feeding on mucosal integrity and the prevention
of bacterial overgrowth may well explain the superiority
of enteral feeding over TPN. Enteral feeding signiﬁcantly
reduces the risk of infections, lowers the need for surgical
interventions, and reduces the length of hospital stay. In
the past few years, it has been proposed that EN through
nasogastric (NG) tubes may be a simple, safe, and equally
valid alternative to nasojejunal tubes, with the potential
advantage of earlier administration of nutrients. However,
NG feeding cannot be recommended at this time, and it is
not clear if a subgroup of SAP patients may beneﬁt more
from this approach [31–35].
The facts that EN is most likely superior to parenteral
nutrition in preventingseptic complicationsofacutepancre-
atitis,mayalso eliminatesomecomplicationsofPN(catheter
sepsis, pneumothorax, and thrombosis), and costs only 15%
of the cost of TPN, make it an increasingly accepted treat-
ment modality [36]. Windsor et al. randomized 34 patients
toTPNorenteralnutritionfor7days.Theyreported thatthe
reduction in inﬂammatory response with enteral nutrition
could be ascribed to the suppression of bacterial overgrowth
rather than to the reduction in pancreatic injury. This
observation was supported by the ﬁnding of (1) no increase
in screenendotoxinantibodies inthe enteral nutrition group
as compared to an increase in the TPN group (P<. 05)
and (2) no diﬀerence in CT evaluation of the pancreatic
injury after enteral nutrition or TPN. There is accumulating
clinical evidence that enteral nutrition can improve survival
and reduce the complications accompanying the severe acute
pancreatitis. The explanations are complex and related to
the fact that (1) enteral nutrition avoids TPN complications,
(2) luminal nutrition maintains intestinal health, (3) enteral
amino acids are more eﬀective in supporting splanchnic
protein synthesis, and (4) enteral nutrition may prevent the
progression of multiple organ failure.
Many clinical and experimental studies have demon-
strated that TPN can promote more cytokine production
compared to EN [37, 38], including IL-6, IL-8, TNF, and
CRP.Total parenteralnutrition has failed toshowany clinical
beneﬁts for the patients, as it cannot protect the gut mucosa.
On the contrary, enteral feeding repairs the mucosal damage
offasting.Ifenteralfeedingisgivenveryearly,itmaypreserve
epithelial integrity and bacterial ecology, thereby helping to
maintain gut barrier function [39]. Doley et al. reported
that patients given TPN were more often infected by Gram-
positive organisms and fungi as compared to those given EN
who were more often infected by a Gram-negative organism.
This observation has an important bearing on the outcome
of severe acute pancreatitis as fungal infection carries a
higher risk of mortality. Though proper aseptic precautions
were maintained, the occurrence of infections with Gram-
positive organisms such as Staphylococci in the TPN group
suggests that it could be due to the invasion of central line
catchers with cutaneous commensals [21].Gastroenterology Research and Practice 7
Petrov et al. reported that extrapancreatic infectious
complications were more frequent in their study (22%) than
those in other studies. In addition to the severity of the
patients included, this is likely due to the prolonged hospital
stay and maintained central venous and urinary catheters. In
fact,catheterinfection was themostfrequentextrapancreatic
infectious complication. In their study, 46% of patients were
found to have infections, and the most common organisms
were Escherichia coli and Pseudomonas aeruginosa,w h i c hi s
similar to earlier reports. It gives an idea about the possible
source of infection. In their series, as well as others, most
of the infections were with Gram-negative bacteria, and up
to one-third of infections in their study were polymicrobial.
This would suggest that the gut was the most likely source of
infection [17].
4.2. Non-Infection-Related Complications. Compared to
TPN, TEN has higher risk of non-infection-related
complications caused by nutrition support. Although TEN
has so many complications, such as diarrhea and abdominal
distension, the risk is much lower than septicemia induced
by tube. Recently, Karakan et al. reported that beneﬁcial
bacteria can reduce diarrhea complications induced by TEN
[40]. Anyway, a number of these complications such as tube
removal or diarrhea are relatively minor and can often be
managed by avoiding liquid and elixir medications that
contain sorbitol (for diarrhea) and use of a nasal bridle in
patients at risk for tube removal.
4.3. MOF and Mortality. This meta-analysis demonstrates
that TEN is superior to TPN in MOF and mortality. But
Doley’s study got the conclusion that there is no diﬀerence
in mortality. But totally, we still support the conclusion that
TEN is superior to TPN.
4.4. Surgical Interventions. The references included in our
study all reported that TEN has less surgical interventions
compared to TPN. But Doley’s study got the conclusion
that there is no diﬀerence in surgical interventions. This
conclusion may be caused by the severity of the patient’s
condition.
5.Disadvantages
We did not perform sensitivity analysis because there is
only on paper with the Jadad score less than two. But there
are still many disadvantages in this meta-analysis. First,
the population included in the study is small. Second, in
Gunilla’s study, the nutritional support way was nasogastric
feeding tube. One new meta-analysis compared nasogastric
feeding tube and nasojejunal feeding tube and showed that
there was no diﬀerence between the two ways in mortality,
hospital stay, infection-related complications, and costs[41].
Third, thetotal number ofpatientsenrolled was limited (n =
335), which may lead to wide CI. Fourth, it is possible that
studies with negative results, which showed no trend in favor
of either intervention, may remain unpublished, leading to
publication bias.
Taken together, this meta-analysis conﬁrmed previous
reports in the literature, especially those from recent years.
This study demonstrated that enteral nutritional support
is safe and eﬀective when compared to parenteral support.
Compared with TPN, EN was associated with a signiﬁcantly
lower incidence of pancreatic infection complications (RR =
0.556, 95% CI 0.436∼0.709, P = .000), MOF (RR = 0.395,
95%CI0.272∼0.573,P = .003),surgicalinterventions(RR=
0.556, 95% CI 0.436∼0.709, P = .000), and mortality (RR =
0.426, 95%CI 0.238∼0.764,P = .167).There was no statistic
signiﬁcance in non-pancreatitis-related complications (RR
= 0.853, 95% CI 0.490∼1.483, P = .017). However, EN
had a signiﬁcantly higher incidence of non-infection-related
complications (RR = 2.697, 95% CI 1.947∼3.735, P = .994).
There was no signiﬁcant diﬀerence in hospital stay between
patients with TPN and EN. However, a deﬁciency of this
study is its retrospective nature and relatively small sample
size. Therefore, studies with larger sample sizes should be
done to better deﬁne the role of enteral nutritional support
in the treatment of severe acute pancreatitis.
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